MSD Animal Health has obtained regulatory approval in 21 European countries, including the UK, for Cobactan LA 7.5% (cefquinome) - a new-generation, injectable antimicrobial for the treatment of swine respiratory disease (SRD).
Raul Berro DVM, global marketing director swine at MSD Animal Health said: "Cobactan LA 7.5% is a long-acting version of our highly effective Cobactan 2.5%. Its longer duration of action means greater compliance for swine producers with fewer injections and less stress to the animals, without sacrificing performance."
According to the company, the long-acting antibiotic formulation is effective against three major SRD pathogens in growing and finishing pigs - Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida. Considered the most important threat to the swine industry worldwide, SRD causes increased mortality, decreased weight gain and increased feed consumption.
Cobactan LA 7.5% requires two intramuscular injections 48 hours apart, compared to Cobactan 2.5%, which requires three daily injections. The recommended dose rate is 1 mL (3 mg cefquinome) per 25 kg bodyweight. The product isavailable in 50-ml, 100-ml and 250-ml glass vials.
Raul aded: "COBACTAN LA 7.5% also has a short withdrawal period of seven days. This makes the injectable product also safe to use throughout the finishing period for the treatment of SRD."
MSD adds that the use of COBACTAN LA 7.5% should be according to established responsible use guidelines and strictly according to the label instructions where specific restrictions apply to this class of antibiotics.
For more information, contact your local MSD Animal Health representative or go to www.msd-animal-health.com.
The 2-day Change Catalyst Veterinary Retreat will take place at Roaches Hall on the Derbyshire/Staffordshire border from 15-17th May 2018, after which participants will receive three months of personal one-to-one coaching.
The organisers say that during the retreat, which is provided in partnership with Natural Change, participants will take part in a series of largely outdoor activities that draw on the potential of nature. They will also be introduced to some simple nature-based techniques to look after their wellbeing and to reflect on their personal or professional journey. Post-retreat personal coaching is included to help reinforce and embed these changes or assist in developing the insights gained during the retreat.
The retreat is aimed at veterinary surgeons who are at a career crossroads, making major decisions about the direction of their career or for those looking for an opportunity to help develop capacity, build resilience and to improve wellbeing. The organisers say it offers time and space to get away from everyday concerns, re-energise and focus on what really matters as well as helping vets reflect, refresh and reconnect with nature.
The retreat is open to a maximum of 16 participants who will work with two facilitators. The follow up coaching is one to one, personal, and confidential.
Director, Adrian Nelson-Pratt said: "Vets have well documented challenges with work-life balance that lead to a disconnection from the natural world. Feelings of isolation, loss of career direction or in the worst-case, deterioration in physical and mental health can follow.
"Having experienced the Natural Change process myself, I found it a deeply reflective and restorative experience. It allowed me the time and space to develop some new ideas and to re-invigorate myself.
"The Change Catalyst Vet Retreat is the result of this process for me and I think it’s a powerful tool to support vets on a personal and professional level. It’s also an appropriate contribution to your annual CPD requirement."
Tickets cost £1500 and are available at https://www.emerge-veterinary.com/join-us/the-change-catalyst/ or for more information contact: adrian@emerge-veterinary.com
Mr Chalkley faced three charges against him. The first was that he failed to identify some or all of the animals tested with Intradermal Comparative Tuberculin (ICT) tests at the farm.
The second charge was that Mr Chalkley had certified that he had carried out ICT tests on 279 animals at the farm and recorded the results on the accompanying paperwork but had, in fact, not adequately identified some or all of the 279 animals and had fabricated the skin thickness measurements recorded for some of them.
In addition, the charge alleged that Mr Chalkley’s conduct was dishonest, misleading and risked undermining government testing procedures designed to promote public health.
The third charge was that between June 2011 and September 2018, Mr Chalkley received payment of approximately £20,000 for ICT tests when, as a result of his conduct in relation to ICT tests at the farm, he was not entitled to such payment.
At the outset of the hearing Mr Chalkley admitted the first charge, that he had not adequately identified some of the animals.
On the third day of the hearing, during his evidence to the Committee, he admitted that his certification of the ICT testing was therefore misleading.
He denied the rest of the charges including that his conduct had been dishonest and that it had risked undermining government testing procedures designed to promote public health.
In considering the charges against Mr Chalkley, the Committee heard that discrepancies regarding the tests that were carried out on the farm in March 2018 were originally raised by the Animal and Plant Health Agency (APHA), on whose behalf Mr Chalkley carried out ICT testing in his capacity as an Official Veterinarian.
When Mr Chalkley gave evidence during the hearing, he explained that he had taken over TB testing for the farm in 2008 and that working conditions on the farm had been difficult throughout the whole period 2008 to 2018. He stated that due to the harsh weather conditions of early 2018, TB testing was difficult, and that the farmer needed to complete the test by March 2018 to avoid a financial penalty.
Mr Chalkley explained that one of the reasons for there being limited time available for him to carry out the test within the time required by the farmer was that he was due to provide veterinary cover at the Cheltenham races the following week and he was unable to find anyone else to cover the tests. Mr Chalkley also explained that during the tests on 5 and 8 March there had been limited farmhands available to assist in processing the cattle through the tests.
In the course of being asked questions by counsel for the RCVS, Mr Chalkley accepted that he had failed to identify some 45% of the animals he had injected on 5 March 2018 and had, in respect of each of the skin thickness measurements for those animals, randomly chosen a figure that he believed would be appropriate based on the breed, age and sex of the animal.
The APHA guidelines state that specific measurements should be made and recorded for each individual animal using callipers. Mr Chalkley said that he could not remember seeing the “pop-up” declaration which appeared when submitting the results to the APHA online and had never read it. He stated that he was not aware that he was making a declaration. However, he accepted that as an Official Veterinarian he was confirming that he had carried out the test properly. While he agreed that he knew that the test contained inaccuracies, he did not accept that he was being dishonest when he submitted the results.
Having considered all the evidence put forward by the RCVS and Mr Chalkley in his own defence, the Committee found that Mr Chalkley had acted dishonestly in deliberately choosing not to take the measurements on 5 March and had instead submitted fabricated alternatives, and so risked undermining public health by failing to carry out his duties as an OV.
The Committee also concluded that Mr Chalkley had been acting dishonestly, as he knew that he was submitting the test results as if they were the authentic outcome of a properly conducted test when in reality, they were no such thing.
The Committee did not accept Mr Chalkley’s evidence that he was unaware of the declaration which accompanied the submission of the test outcome. The Committee therefore found both the first and second charges proved.
In respect of the third charge the Committee found that this was not proven noting that the RCVS had not disproved Mr Chalkley’s explanation regarding his reasons for returning the £20,000 in fees he had received for carrying out TB testing at the farm from the APHA since 2011.
The Committee then considered whether the first two charges, both of which had been found proven, amounted to serious professional misconduct.
Ian Arundale, chairing the Committee and speaking on its behalf, said: “The Committee was prepared to accept that the respondent considered the risk arising from his actions as negligible. Nonetheless, in the Committee’s assessment a real risk existed due to the respondent’s actions and it was precisely the risk which the authorised testing procedure was designed to negate. The simple fact is the respondent could not be sure that each animal he assessed on 8 March 2018 had also been seen by him on 5 March 2018.
“However, the wider point with which the Committee was concerned related to the importance of any member of the profession or public being able to rely absolutely on the integrity of veterinary certification. Those parts of the Code and supporting guidance [concerning certification]… were unequivocal. It was very difficult to conceive of circumstances in which it could ever be justifiable to certify the outcome of a test which had not, in fact, been conducted in a way which was demonstrably valid and reliable. Such conduct was bound to be regarded as disgraceful by members of the profession and the general public.
“Honesty is the bedrock of appropriate certification and the Code and Guidance for the Disciplinary Committee is also unequivocal. Dishonesty in professional practice is always an extremely serious matter and the respondent’s responsibilities in the discharge of his functions as an Official Veterinarian were clear. On this occasion those responsibilities had been compromised.
“For these reasons, the Committee has come to the conclusion that the respondent’s conduct in relation to the facts found proved was disgraceful conduct in a professional respect.”
The Committee then went on to consider the sanction for Mr Chalkley.
The Committee heard oral evidence in mitigation, including from a former colleague who had worked with him in practice since 2006, as well as receiving a large number of written testimonials from various sources that attested to his honesty, integrity, willingness to help others, and charitable work in support of animal welfare.
Mr Chalkley’s counsel, in mitigation, highlighted his long and previously unblemished career, and characterised the conduct as an inexcusable but explicable error of judgement that was entirely isolated and out-of-character. Mr Chalkley’s counsel added that he had not done anything that he thought was seriously wrong, and there was no evidence that any harm had been done and that any risk to public health was not serious.
The Committee accepted that the conduct was isolated and out-of-character and that, furthermore, Mr Chalkley had made early and frank admissions to the APHA and that he had displayed a degree of insight, although the Committee was less confident that he truly understood the seriousness of the potential consequences of his dishonest conduct.
The Committee took into account the aggravating factors, including Mr Chalkley’s breach of trust of his position as an OV, the undermining of the integrity of veterinary certification, dishonesty and the potential public health impacts of his conduct.
Ian Arundale added: “The Committee considered that, having regard to the mitigating features which it had identified, a suspension order would be sufficient to send to the profession and the public a clear signal about the importance to be attached to accurate certification. The Committee considered that in the particular circumstances of this case, a period of three months suspension would be sufficient to achieve this objective.”
The full findings for the case can be found at: www.rcvs.org.uk/disciplinary
The company says its new design is modular, allowing veterinary practices to customise kennels to their requirements now, and then upgrade them and add components as their needs change over time.
Options include dimmable daylight lighting or Casco Pet’s DRC Lighting System with three modes: Daylight (white), Recovery (red), and Cleaning (blue UVA), built-in thermostatically controlled heat mats, an illuminated glass whiteboard for easy recording and viewing of patient notes, integrated IV stand and pump holders, an internal ceiling vent and ventilation kit and an integrated plug socket and USB port .
Matthew Bubear, CEO, Casco Pet, said: “Our new generation of WellKennels, which have been designed to meet the dynamic demands of modern veterinary practices, allow practitioners to elevate the care they provide today while ensuring sustained adaptability for the needs of tomorrow."
WellKennels are certified by the International Society of Feline Medicine and are part of FearFree’s Preferred Product Program, the global initiative dedicated to preventing and alleviating fear, anxiety and stress in pets.
The new WellKennels will be unveiled at the London Vet Show, ExCel London, 16-17 November, on Stand H35.
https://cascopet.com/uk/products-and-services/veterinary
Unite, the largest trade union in the country, has announced that up to 17,000 members of the UK veterinary profession could become members within the next five years, following the establishment of the British Veterinary Union (BVU)The union says it will be able to give veterinary surgeons, veterinary nurses, practice managers, support staff and students in all disciplines, the additional muscle to tackle employment problems in the workplace, such as pay, contracts, bullying and professional development.Unite's General Secretary, Len McCluskey said: 'As a progressive trade union, Unite warmly welcomes BVU into the Unite family. The fact that a highly-regarded profession is looking to Unite for support in employment matters is an indication of the validity and relevance of trade unions in 2011 Britain.' Dr Shams Mir, Chairman, Professional Advisory Committee, British Veterinary Union in Unite said: 'Our biggest challenge will be to change the mindset of our profession to address the deep-trenched problems of working conditions and terms of employment for vets and nurses, and safeguarding their professional status. But, most importantly, we have to overcome the sense of fear amongst veterinary professionals in raising legitimate employment issues.''Veterinary professionals face the same problems in their working lives as any other health professionals, but never before have vets had a trade union to support and represent them. BVU in Unite is a great opportunity for the profession to develop and expand, and is a goal that many have aspired to for years. We believe that up to 17,000 veterinary professionals could join BVU in Unite in the next five years.'Dr Mir said that research has revealed that vets suffer from much higher levels of anxiety and depressive symptoms and they are five times more likely to have suicidal thoughts and four times more likely to commit suicide compared to the general UK population.
He said: 'Sadly, according to the most recent Royal College of Veterinary Surgeons' survey of the profession, nearly half of the responding vets and nurses said that if they had their time again, they would choose a different profession.' 'This is a wake-up call for our profession and we must act to address all the underlying problems leading to this situation.'
Further information is available at: www.bvu.org.uk and www.unitetheunion.org/bvu
The London Vet Show was a runaway success this year, with more delegates on day one than visited the entire show in 2010.
Rob Chapman from CloserStill Media, organiser of the event said: "We're still number crunching, but it looks like numbers were up something like 40% on last year."
VetSurgeon.org visited the event and filmed a number of the commercial exhibitors, many of whom said what a good atmosphere there was at the show and how busy it was.
CloserStill has already confirmed that the London Vet Show will again take place in the Grand Hall at London Olympia next year. However, it will be expanding into West Hall for the clinical lectures, so that everyone can have a seat, unlike this year when demand was so high, some had to sit on the floor.
Boehringer Ingelheim Vetmedica has launched Pexion (imepitoin) a novel treatment for canine idiopathic epilepsy.
Canine epilepsy can affect up to 5% of dogs6. In most dogs diagnosed with idiopathic epilepsy no underlying cause for the seizures can be found. While the condition can affect any dog, it is more common in young (one to five year old), purebred dogs such as Labradors, Golden Retrievers, German Shepherds, Boxers, Vizlas, Beagles, English Springer Spaniels, Irish Setters, Poodles and Dachshunds.
Boehringer says Pexion has a highly targeted mode of action1-3 to suppress a dog's seizures. It starts to work within a few hours and reaches steady state within three days4,5. Boehringer claims this will make it easier to stabilise epileptic patients. It also says there is no evidence of hepatotoxicity or liver-associated enzyme elevation, so repeated blood tests for liver enzymes or therapeutic levels are no longer required.4,5
Pexion is available in 100 mg and 400 mg tablets. The tablets are white, scored and divisible in half. Both tablet strengths are available in 100 tablet packs from veterinary wholesalers.
Jemima Mead, brand manager at Boehringer said: "Pexion is a ground-breaking new product which gives vets a new first-line treatment option for dogs with idiopathic epilepsy, improving the lives of newly diagnosed epileptic dogs and their owners by reducing the number of seizures and their impact on the patient's life".
To support the launch of the new product, Boehringer hosted an epilepsy webinar presented by neurologist Dr Holger Volk DVM PhD DipECVN FHEA MRCVS, recognised RCVS and European Specialist in Veterinary Neurology. The webinar is now available on demand at www.bi-academy.co.uk.
For further information on Pexion visit www.pexion.co.uk, contact your local Boehringer Ingelheim territory manager or telephone +44 (0)1344 746959.
References
The awards are designed to recognise successful implementation of quality improvement (QI) in veterinary practice, which can reduce avoidable errors, ensure practice is based on the best available evidence and, ultimately, save lives.
Entrants will need to demonstrate the impact that QI methods have had in their practice, such as increased efficiency, improved clinical or financial effectiveness, the development of a culture of continuous improvement, support in the use of evidence-based approaches, or a general bettering of excellence in care.
The awards are open to any member of a practice, including veterinary surgeons and nurses, practice managers, receptionists, locums, students, and more. You can also nominate a colleague, or vice versa.
Individual winners will get free tickets to an upcoming RCVS Knowledge event and be given a plaque pronouncing them a 'Knowledge Champion', while one team will scoop Knowledge’s 'Champion Practice' award.
RCVS Knowledge Executive Director Chris Gush said: "These awards are a great opportunity to celebrate the good work that is going on in practice and to highlight examples of quality improvement.
"I would encourage all – from quality improvement experts to QI beginners – to get involved and enter the awards."
The closing date to submit an application is 1st November 2018, allowing plenty of time for those interested in introducing a quality improvement initiative in their practice to do so and apply for the awards at a later date.
To learn more about QI and how you can get started, visit RCVS Knowledge's QI pages.
Alternatively, you can enter the awards here: https://knowledge.rcvs.org.uk/grants/available-grants/
The intranasal vaccine can be administered to calves from one week old. It reduces the clinical signs of respiratory disease and viral shedding from infection with Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3V).
MSD says that no other UK-licensed BRD vaccine can be administered earlier in life, and claims the vaccine delivers the fastest on-farm protection, with an onset of immunity after administration of 5 days for BRSV and 7 days for Pi3V. Duration of immunity is 12 weeks for both viruses.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: "Having this early life calf pneumonia vaccine available in single dose vials will give farmers more practical leeway to be able to vaccinate vulnerable young calves from as young as a week of age, rather than delaying administration until a batch of calves are available. We know that early-age protection of young calves through intranasal vaccination can help prevent pneumonia and positively impact a beef or dairy calf’s productive future".
The new single dose vials are supplied in packs of five, complementing the five dose vials already available.
For further information, contact your MSD account manager.
Canaural contains fusidic acid, framycetin and nystatin for their antibacterial and antifungal effects against the most common organisms associated with otitis externa.
Fusidic acid has skin penetrating properties and is active against staphylococci and streptococci1. Framycetin is active against Gram negative species. Dechra says the combination of the two provides an enhanced antibacterial effect on the most common bacterial cause of canine otitis2.
Nystatin is active against malassezia and prednisolone helps to provide anti-inflammatory and anti-pruritic action.
Dechra Brand Manager Carol Morgan said: “The reintroduction of Canaural to the veterinary treatment market means that once again veterinarians have this reliable and effective treatment available to tackle one of the most common canine complaints.
"Canaural is a tried and tested product and a recent study showed that fusidic acid is highly efficacious against both methicillin sensitive and methicillin resistant strains of Staphylococcus pseudintermedius3. Canaural remains as relevant today as it has ever been."
Canaural comes in 15 ml and 25 ml bottle sizes and is now available in veterinary wholesalers.
The company says more and more CT scanners are being used in general practice, but many teams have been telling them they're not sure if they're using their scanner optimally, or that only some of the team are confident in using it.
The online training aims help teams get the best diagnostic use of CT
The first of the sessions, on 15th June, will cover the indications and benefits of CT in small animal practice.
The second on 22nd June will look at how and when to perform CT reconstructions.
Manuel Pinilla, VetCT Supporting Radiologist and Director of Quality Assurance (pictured right), will be delivering the talks.
Manuel said: “We are seeing a rapid increase in the use of CT in first opinion practice.
"We know CT can provide vital diagnostic information in addition to the more traditional modalities of x-ray and ultrasound.
"However, it can be challenging to optimise the diagnostic capability.
"We’re keen to support veterinary teams to help them get the most out of their machine and do the best for their patients and the owners.”
To register for the training, visit: https://welcome.vet-ct.com/ctcpdwebinars
Last year Petplan received over 31,000 nominations across the five award categories: Practice of the Year, Vet of the Year, Vet Nurse of the Year, Practice Manager of the Year and Practice Support Staff of the Year.
The awards are judged by an independent panel which narrows the field to three finalists in each category, who are then invited to attend the awards ceremony.
The judges are looking for examples of exceptional levels of animal care, building and sustaining great relationships with colleagues and pet owners, and those who have gone above and beyond the call of duty.
James Barnes, Head of Sales & Partnerships at Petplan, said: “The Petplan Veterinary Awards provide the perfect opportunity to say thank you for the exceptional work carried out by members of the veterinary profession, whatever their field and wherever they’re based. The Petplan Vet Awards provide a great opportunity for both clients and colleagues to recognise the dedication and talent of veterinary professionals, teams and practices, right across the UK and say a particular thank you to those who have kept up the exceptional level of care even in the midst of a global crisis."
To nominate a colleague or your practice, visit www.petplan.co.uk before nominations close on 10th January 2022.
Speakers include Prof. Jo Dukes McEwan, Head of Service, Professor in Small Animal Cardiology (University of Liverpool), Doctor Jennifer Schissler, Veterinary Dermatologist, Best Friends Animal Hospital & Urgent Care Unit (US), and Doctor Pascal Prélaud, Dermatologist, CEO ADVETIA Vet Hospital Center (France).
Participants will also be able to access to an immersive experience, the Vet Symposium Village, which includes the Live Stage, Vet Lab, Clinic Lounge, and Innovation Hub, all offering exclusive videos and lectures.
The event will be translated into Chinese, French, Spanish, Italian, Portuguese, Russian, and German, and a replay of the event will be available until the end of the year.
Dr. Jennifer Welser, Chief Medical Officer, Mars Veterinary Health, said: “It’s more critical than ever for pet professionals from various countries, fields, and perspectives to meet and share their knowledge.
"I look forward to participating in the Vet Symposium and speaking with my peers on topics ranging from mental health to advancements in quality medical care and retaining veterinary talent.”
https://digital-vetsymposium2022.com/
Invicta Animal Health has announced its appointment as exclusive veterinary distributor in the UK for Chloraprep, a licensed human product for cutaneous antisepsis, prior to invasive procedures.
Invicta says Chloraprep is a single use, easy to apply, sterile system, available in a variety of sizes and in clear and tinted versions to enhance the visibility of the area requiring antisepsis, for instance, prior to surgery.
The sterile solution is maintained in a glass ampoule inside a protective outer case and, to prevent contamination, the patented design ensures users don't come into contact with either the contents or the patient's skin.
Rob Watkins, Managing Director of Invicta, said: "Most surgical site infections (SSI's) are the result of contamination from a patient's own skin flora1, a fact which highlights the importance of thorough and effective preparation of the skin as a proactive way to minimise the incidence of SSI's in patients."
According to the company, research has shown that Chloraprep, which contains 2% chlorhexidine and 70% isopropyl alcohol, has demonstrated significantly better antimicrobial activity than other combinations2.
Invicta says the way in which the solution is applied to the skin is as important as the solution itself. Studies show that the most effective way to apply Chloraprep is with a back and forth scrubbing movement because this gives a lower microbial count on the skin than using other application methods3. Once applied, Chloraprep is active in 30 seconds and is effective for up to 48 hours4.
Rob said: "The majority of UK hospitals and the Blood Transfusion Service already use Chloraprep and we are pleased to make this available under the provisions of the cascade."
He added: 'The veterinary nurses I've spoken to love this product, because they're fed up of immersing their dry, cracked hands in disinfectant!'
For further information, please contact Invicta Animal Health on 01403 791313 or email the company at mail@invictavet.com.
1. Florman S, Nichols RL. Am J Infect Dis 2007; 3: 51-61.2. Hibbard JS. J Infus Nurs 2005; 28: 194-207.3. Rosenthal K. Nurs Manage 2006; April: 55-66.4. Garcia R et al. Abstracts of the IDSA 40th Annual Meeting 2002; Abs 418.
Virbac has launched Prinovox, a new prescription-only spot-on ectoparasiticide for dogs and cats.
The company says the new product contains the same combination of Moxidectin and Imidacloprid as the market leader, but is offered with a unique and innovative pet owner engagement programme to help practices build loyalty, increase compliance and to encourage repeat purchase.
In dogs Prinovox is licensed for the treatment and prevention of lungworm; for the treatment and prevention of fleas and also for lice, mites, heartworm and roundworms. In cats, the licence covers fleas, mites, roundworm and heart worm. It can also be used for fleas and heartworm in ferrets.
Prinovox is available in six presentations to suit all weight ranges and in packs of four pipettes. The packaging uses the Blippar platform which owners can use to 'blip' interactive icons on the product's packaging with their smartphone to get more information on Prinovox, including a video on how to use it, a reminder system and a game.
In addition, the Prinovox support package includes:
Virbac's Head of Marketing Companion Animal, Simon Boulton MRCVS said: "We see the launch of Prinovox as a gamechanger. The ectoparasiticide market is one of the largest and most competitive in our industry and we are the first company to offer a product with the same efficacy as the market leader for all indications.
"We've gone one step further by increasing the value of the product to practices by developing a comprehensive parasite protection support package which harnesses the latest technology and consumer preferences for receiving information. We believe the efficacy of Prinovox, combined with the innovative support package we're offering, will make it a highly attractive product for practices and owners and we've been delighted at the feedback we've received so far."
Forte developed the new solution alongside Professor Gayle Hallowell, Professor of Veterinary Internal Medicine and Critical Care at the School of Veterinary Medicine and Science, University of Nottingham.
The company says Hydrafast delivers ideal levels of sodium and glucose. It also contains glycine, an amino acid, acetate, propionate and citrate.
Professor Hallowell said: “This new ORS formula for calves is both practical and research-based, and should address what we know calves need when they have diarrhoea. It provides nutrition as well as an optimal electrolyte balance.”
Hydrafast comes in sachets of 133g. Each box of Hydrafast contains 24 sachets.
Hydrafast is available now from all major veterinary wholesalers, or direct from Forte Healthcare Ltd.
For more information contact your Forte Territory Manager, email enquiries@fortehealthcare.com or visit: www.fortehealthcare.com/product/hydrafast/
whatstherisk.co.uk has been created for all practice staff and contains advice from parasitologists Ian Wright and Eric Morgan.
Topics include advice on practical risk assessments, how risk-based prescribing can work with health plans as well as how to get owners involved to make risk assessment and personalised prescribing quicker and simpler.
Boehringer says that all the materials and advice have been developed in line with RCVS Practice Standards and the BVA's guidance on the responsible use of parasiticides.1,2
Sharron Woods, NexGard brands Franchise Manager said: “With knowledge about parasitic risk low among dog owners, alongside increasing scrutiny on the potential overuse of parasiticides, we’re delighted to be at the forefront of supporting vets, pet owners and the wider industry in driving best-practice risk assessment and responsible parasite control."
MSD says the new license claim means the vaccine combines the broadest calf scour protection available with unique user convenience.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: “When correctly administered as a single 2ml intramuscular dose to pregnant cattle 12-3 weeks prior to calving, Bovilis Rotavec Corona boosts antibodies in colostrum for rotavirus, coronavirus and now both E.coli F5 (K99) and F41.
"Calves gain protection against these infectious scour pathogens by drinking the fortified colostrum from their vaccinated mothers.
“Bovilis Rotavec Corona also contains the most prevalent rotavirus strain in Europe2, which minimises the chances of a calf scour protection breakdown due to differences between vaccine antigens and the ubiquitous antigens on farm3.”
Kat added: "Vet, RAMA and farmer feedback suggests the wide vaccination window (12-3 weeks pre-calving) and the fact that an opened bottle of vaccine lasts for up to 28 days are particularly useful practical benefits in a mix of both dairy and beef suckler systems.”
Bovilis Rotavec Corona is available in 5, 20 and 50-dose packs from both veterinary professionals and the agricultural merchant trade.
Elanco Animal Health has highlighted the results of a new study1 which concludes that Duvaxyn IE-T Plus stimulates a highter protective antibody response than four other equine influenza vaccines commercially available in Ireland.
The trial compared the antibody responses of unvaccinated Thoroughbred weanlings following primary vaccination with Duvaxyn IE-T Plus, Equilis Resequin, Equip FT, Equilis Prequenza Te and ProteqFlu Te.
In addition, following the first vaccination, 43% of the weanlings failed to seroconvert. However, amongst those vaccinated with Duvaxyn IE-T Plus a 100% response rate was observed. The failure rate amongst vaccines other than Duvaxyn IE-T Plus ranged between 7.7% and 78.6%. By the time of the third vaccination (31 weeks after the first) all horses had responded to vaccination.
The study, conducted by the Irish Equine Centre in Johnstone, the Department of Life Sciences at the University of Limerick and the Department of Statistics at Trinity College in Dublin, involved 66 unvaccinated Thoroughbred weanlings on four different stud farms. Following primary vaccination (V1, V2 and V3) with the five vaccines antibody responses were monitored for six months post V3 by single radial haemolysis. Elanco says that the correlation between SRH antibody levels and protection has been well-established and accepted2.
Elanco also highlights a recent study3 which it says demonstrated the ability of Duvaxyn IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Richmond/1/07 (H3N8) two weeks after a two dose primary course. The company says that this is believed to be the first demonstration of cross protection by a current UK equine influenza vaccine against a Florida sub-lineage clade 2 reference strain.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health said: "Most studies carried out by vaccine companies take place under controlled conditions that are optimal for effective vaccination. This latest study shows how well Duvaxyn IET plus stimulates immunity under field conditions against both vaccinal and non-vaccinal strains. Importantly, all the weanlings vaccinated with Duvaxyn seroconverted after the first vaccination, conferring earliest and most reliable protection for these vulnerable animals."
For further information please contact your local Elanco Companion Animal Health key account manager or phone 01256 779881.
References:
Phil Kenward from Farm Vets South West in Bridgewater, Somerset has won a bottle of port from the Veterinary Benevolent Fund for submitting the best practical veterinary tip.
The tip was:
"Do not allow the owner's diagnosis of his problem to worry or influence you before you examine the animal yourself."
The competition was run to celebrate the launch of The Pocket Book of Tips For Practising Vets which can be ordered on-line from the Vetlife website to raise funds for the VBF charity.
Lydia Brown, President of the VBF, said: "This book has been a monumental effort by six mixed practice vets, to both share their experience with the profession and to provide very welcome funds for the veterinary profession's own charity, the VBF. We are currently raising money for the new Vet Helpline e-mail support service which will launch at the end of the year so we are extremely grateful to everybody concerned for all their efforts."
Pets at Home has announced the acquisition of the joint venture practice business, Vets4Pets, adding 93 stand-alone veterinary practices to the 116 in-store practices it already operates under the Companion Care brand.
Providing veterinary and grooming services to consumers is seen as the way for the retailer to overcome competition from the Internet.
Nick Wood, CEO of Pets at Home said: "The expansion of our veterinary business is a key element of our growth strategy for Pets at Home, providing additional services to our customers within our stores or close to our customers' homes. The acquisition of Vets4Pets is an important step in the delivery of this strategy. Vets4Pets is highly complementary to Companion Care, sharing fundamental beliefs and values, and is an excellent strategic fit for Pets at Home. I am delighted that Peter Watson has agreed to stay with the business. His knowledge and experience will be invaluable as we continue to build our veterinary business with both stand-alone and in-store practices. He will work closely with Jane Balmain, the Managing Director of our Companion Care business as we integrate the two businesses."
Peter Watson, Founder and CEO of Vets4Pets said: "Pets at Home holds a unique place in the retail landscape, built on a strong identity and a real passion for people and pets. It is clear to me that Nick and his team have a similar vision for their veterinary business. I'm delighted to be working with Nick to continue to expand the veterinary business by offering attractive joint venture opportunities for vets in stand alone locations to complement the offering in Pets at Home stores."
Companion Care MD, Jane Balmain added: "Companion Care and Vets4Pets each enjoy a strong reputation among both vets and customers. Both businesses have a common business model, offering joint venture partnerships with vets. I am looking forward to working alongside Peter as we bring the businesses together, continue to expand our joint venture partnerships and accelerate our growth."
Vets4Pets' UK operational centre will remain in the East Midlands, with its support functions being split between Companion Care's operation in Oxfordshire and Vets4Pets' Guernsey office.
The Federation of European Companion Animal Veterinary Associations (FECAVA) has announced the online publication of the Winter edition of its journal, EJCAP, which leads on responsible use of antibiotics and is now available free to all members of the veterinary profession.
The latest edition also features articles about indoor ferrets and hyperadrenocorticism, elderly cats and osteoarthritis, and correcting a malocclusion.
As a result of a unanimous decision by the FECAVA Council in October, the journal is now freely available to all veterinary practitioners, students and nurses throughout Europe.
To access the journal, visit: http://ejcap.fecava.org
Invicta Animal Health has announced the launch of Ocuvance, a nutritional supplement to support ocular health in dogs and cats.
The company says Ocuvance is formulated to provide an antioxidant complex supporting and maintaining the health of eyes. The tablets contain lutein, a xanthophyll pigment found within the eye. They also contain anthocyanosides derived from bilberry extract to support rhodopsin production. The formulation also contains vitamins C and E, zinc and selenium.
Ocuvance is presented in packs of 30 scored tablets; sufficient for a one month supply for the average sized dog.
Rob Watkins, Managing Director of Invicta, said: "We are delighted to make Ocuvance available to veterinary surgeons in the UK. A recent veterinary study1 has shown there can be significant ophthalmic benefits of antioxidant supplementation.
We carefully formulated Ocuvance to provide a range of high quality ingredients to maintain normal visual function whilst still being affordable for owners”.
Ocuvance is now available from all veterinary wholesalers.
Reference
The relevant section of the Government advice states: "This [key worker status] includes those involved in food production, processing, distribution, sale and delivery, as well as those essential to the provision of other key goods (for example hygienic and veterinary medicines)."
The RCVS/BVA statement, which is intended to help veterinary surgeons decide whether or not they can claim ‘key worker’ status and ask for their children to continue to be taken into schools, reminds veterinary surgeons to consider the wider societal picture and ensure that they only claim ‘key worker’ status if absolutely necessary.
The statement also stresses that the RCVS Code of Professional Conduct responsibility of the veterinary surgeon to take steps to provide 24-hour emergency first aid and pain relief to animals according to their skills and the specific situation continues, and veterinary practices will need to continue to carry out this work. It is important that animal owners are able to focus on their own health, and not need to worry about their pets. Both the RCVS and BVA believe that veterinary surgeons who are providing this essential work can be considered key workers.
The statement in full is as follows:
Veterinary surgeons as key workers in relation to school closures
RCVS and BVA appreciate that veterinary surgeons will feel a great deal of uncertainty at the present time, and that many will be facing considerable difficulties due to the closure of schools for most pupils.
The official government advice can be found here: https://www.gov.uk/government/publications/coronavirus-covid-19-maintaining-educational-provision/guidance-for-schools-colleges-and-local-authorities-on-maintaining-educational-provision.
The guidance emphasises that if children can be at home then they should be, in order to help to prevent the virus from spreading.
The government has granted key worker status by sector rather than profession. Some veterinary work will definitely fall into the ‘key worker’ category. RCVS and BVA are therefore providing some additional advice below, following consultation with the UK Chief Veterinary Officer:
SummaryAt this time the provision of public health and the maintenance of food production need to take priority, and veterinary surgeons working in these areas should be considered key workers.
Veterinary surgeons working in emergency care can also be considered key workers. This will not apply to every veterinary surgeon in clinical practice, and practices may need to consider rationalising their services to achieve this.
The guidance has been welcomed by both the BSAVA and BEVA. David Mountford, Chief Executive of BEVA said: "As veterinary professionals we are duty-bound to provide essential care, relieve suffering and protect the health of the public. Recognition as key workers in such circumstances is welcomed but we would encourage vets to only add to the burden faced by schools where animal welfare is at risk and all other avenues have been explored."
For veterinary nurses, Schedule 3 is arguably one of the most important aspects of the Veterinary Surgeons Act, partly defining what it means to be a nurse, and defining what tasks veterinary surgeons can reasonably delegate.
Thus far, however, Schedule 3 has only been loosely defined, allowing for veterinary nurses to (under the direction of their veterinary surgeon employer) 'give medical treatment or carry out acts of minor surgery, not involving entry into a body cavity'.
There is evidence from the RCVS/BVNA VN Futures project that uncertainty about what this definition actually means in practice has stopped veterinary surgeons from delegating tasks which could both improve practice efficiency and make the role of the veterinary nurse more interesting, varied and rewarding.
The consultation - and the broader review of Schedule 3 of which it forms a part - aims to create a 'clarified and bolstered VN role via a reformed Schedule 3'.
Liz Cox, Chair of both the Schedule 3 Working Party and VN Council, said: "The future of veterinary nursing is both challenging and exciting, with the convergence of such factors as Brexit, the development of new technologies, and the increasing specialisation of veterinary surgeons, and we would very much like to know how you think the role of veterinary nurse will evolve.
"In light of this we very much encourage all veterinary nurses and veterinary surgeons to complete this consultation. Evidence gathered during the initial stage of the VN Futures project suggested that there is some uncertainty around the interpretation of Schedule 3 in clinical practice. For example, many veterinary nurses do not undertake Schedule 3 work or are uncertain as to whether they do, while some veterinary surgeons are reluctant to delegate Schedule 3 tasks to veterinary nurses.
"With this survey we hope to get a better steer on how Schedule 3 is used and interpreted in practice on a day-to-day basis and gather views on where both veterinary surgeons and veterinary nurses feel the current legislation could be clarified. Furthermore, we also want to know if there are areas of practice that are currently prohibited to nurses under current Schedule 3 arrangements that the professions believe could be opened up to veterinary nurses as a means of bolstering the profession."
Liz Cox and David Catlow MRCVS, Chair of the Standards Committee, will also be presenting a webinar on Thursday 11 May from 1pm to 2pm titled ‘The Art of Delegation – Schedule 3 Consultation’. It will focus on Schedule 3 and the role of the veterinary nurse, and explore possible areas to consider when responding to the consultation. To subscribe to the webinar, please visit The Webinar Vet’s website: www.thewebinarvet.com/webinar/art-delegation-schedule-3-consultation/
All eligible veterinary nurses and veterinary surgeons have been emailed with a link to survey.
Further information about the VN Futures project can be found at www.vetfutures.org.uk/vnfutures